|
[1]
|
Al-Samkari, H. (2024) How I Treat Bleeding in Hereditary Hemorrhagic Telangiectasia. Blood, 144, 940-954. [Google Scholar] [CrossRef] [PubMed]
|
|
[2]
|
Al Tabosh, T., Al Tarrass, M., Tourvieilhe, L., Guilhem, A., Dupuis-Girod, S. and Bailly, S. (2024) Hereditary Hemorrhagic Telangiectasia: From Signaling Insights to Therapeutic Advances. Journal of Clinical Investigation, 134, e176379. [Google Scholar] [CrossRef] [PubMed]
|
|
[3]
|
Jackson, S.B., Villano, N.P., Benhammou, J.N., Lewis, M., Pisegna, J.R. and Padua, D. (2017) Gastrointestinal Manifestations of Hereditary Hemorrhagic Telangiectasia (HHT): A Systematic Review of the Literature. Digestive Diseases and Sciences, 62, 2623-2630. [Google Scholar] [CrossRef] [PubMed]
|
|
[4]
|
Faughnan, M.E., Mager, J.J., Hetts, S.W., Palda, V.A., Lang-Robertson, K., Buscarini, E., et al. (2020) Second International Guidelines for the Diagnosis and Management of Hereditary Hemorrhagic Telangiectasia. Annals of Internal Medicine, 173, 989-1001. [Google Scholar] [CrossRef] [PubMed]
|
|
[5]
|
McDonald, J., Bayrak-Toydemir, P. and Pyeritz, R.E. (2011) Hereditary Hemorrhagic Telangiectasia: An Overview of Diagnosis, Management, and Pathogenesis. Genetics in Medicine, 13, 607-616. [Google Scholar] [CrossRef] [PubMed]
|
|
[6]
|
Shovlin, C.L. (2010) Hereditary Haemorrhagic Telangiectasia: Pathophysiology, Diagnosis and Treatment. Blood Reviews, 24, 203-219. [Google Scholar] [CrossRef] [PubMed]
|
|
[7]
|
Shovlin, C.L., Guttmacher, A.E., Buscarini, E., Faughnan, M.E., Hyland, R.H., Westermann, C.J.J., et al. (2000) Diagnostic Criteria for Hereditary Hemorrhagic Telangiectasia (Rendu-Osler-Weber Syndrome). American Journal of Medical Genetics, 91, 66-67. [Google Scholar] [CrossRef] [PubMed]
|
|
[8]
|
Chetcuti Zammit, S., Sanders, D.S., McAlindon, M.E. and Sidhu, R. (2019) Optimising the Use of Small Bowel Endoscopy: A Practical Guide. Frontline Gastroenterology, 10, 171-176. [Google Scholar] [CrossRef] [PubMed]
|
|
[9]
|
Hammill, A.M., Wusik, K. and Kasthuri, R.S. (2021) Hereditary Hemorrhagic Telangiectasia (HHT): A Practical Guide to Management. Hematology, 2021, 469-477. [Google Scholar] [CrossRef] [PubMed]
|
|
[10]
|
Kritharis, A., Al-Samkari, H. and Kuter, D.J. (2018) Hereditary Hemorrhagic Telangiectasia: Diagnosis and Management from the Hematologist’s Perspective. Haematologica, 103, 1433-1443. [Google Scholar] [CrossRef] [PubMed]
|
|
[11]
|
Faughnan, M.E., Palda, V.A., Garcia-Tsao, G., Geisthoff, U.W., McDonald, J., Proctor, D.D., et al. (2009) International Guidelines for the Diagnosis and Management of Hereditary Haemorrhagic Telangiectasia. Journal of Medical Genetics, 48, 73-87. [Google Scholar] [CrossRef] [PubMed]
|
|
[12]
|
Sandhu, S., Gross, J. and Barkin, J.A. (2025) Small Bowel Bleeding Due to Vascular Lesions: Pathogenesis and Management. Current Gastroenterology Reports, 27, Article No. 37. [Google Scholar] [CrossRef] [PubMed]
|
|
[13]
|
Peng, H., Yi, Y., Zhou, S., Xie, S. and Zhang, G. (2015) Thalidomide Effects in Patients with Hereditary Hemorrhagic Telangiectasia during Therapeutic Treatment and in Fli-EGFP Transgenic Zebrafish Model. Chinese Medical Journal, 128, 3050-3054. [Google Scholar] [CrossRef] [PubMed]
|
|
[14]
|
Xi, Z., Jie, W., Long, Z. and Shasha, S. (2025) A Review of Thalidomide and Digestive System Related Diseases. Frontiers in Oncology, 15, Article 1543757. [Google Scholar] [CrossRef] [PubMed]
|
|
[15]
|
Ugur, M.C., Baysal, M. and Umit, E.G. (2024) The Role of Thalidomide and Its Analogs in the Treatment of Hereditary Hemorrhagic Telangiectasia: A Systematic Review. Journal of Clinical Medicine, 13, Article 5404. [Google Scholar] [CrossRef] [PubMed]
|
|
[16]
|
Buscarini, E., Botella, L.M., Geisthoff, U., Kjeldsen, A.D., Mager, H.J., Pagella, F., et al. (2019) Safety of Thalidomide and Bevacizumab in Patients with Hereditary Hemorrhagic Telangiectasia. Orphanet Journal of Rare Diseases, 14, Article No. 28. [Google Scholar] [CrossRef] [PubMed]
|
|
[17]
|
Invernizzi, R., Quaglia, F., Klersy, C., Pagella, F., Ornati, F., Chu, F., et al. (2015) Efficacy and Safety of Thalidomide for the Treatment of Severe Recurrent Epistaxis in Hereditary Haemorrhagic Telangiectasia: Results of a Non-Randomised, Single-Centre, Phase 2 Study. The Lancet Haematology, 2, e465-e473. [Google Scholar] [CrossRef] [PubMed]
|
|
[18]
|
Bwire, R., Freeman, J. and Houn, F. (2010) Managing the Teratogenic Risk of Thalidomide and Lenalidomide: An Industry Perspective. Expert Opinion on Drug Safety, 10, 3-8. [Google Scholar] [CrossRef] [PubMed]
|
|
[19]
|
Hulin, C., Facon, T., Rodon, P., Pegourie, B., Benboubker, L., Doyen, C., et al. (2009) Efficacy of Melphalan and Prednisone Plus Thalidomide in Patients Older than 75 Years with Newly Diagnosed Multiple Myeloma: IFM 01/01 Trial. Journal of Clinical Oncology, 27, 3664-3670. [Google Scholar] [CrossRef] [PubMed]
|
|
[20]
|
Hanny Al-Samkari,, Raj S. Kasthuri,, Joseph G. Parambil,, Hasan A. Albitar,, Yahya A. Almodallal,, Carolina Vázquez,, et al. (2020) An International, Multicenter Study of Intravenous Bevacizumab for Bleeding in Hereditary Hemorrhagic Telangiectasia: The Inhibit-Bleed Study. Haematologica, 106, 2161-2169. [Google Scholar] [CrossRef] [PubMed]
|
|
[21]
|
Plummer, C., Michael, A., Shaikh, G., Stewart, M., Buckley, L., Miles, T., et al. (2019) Expert Recommendations on the Management of Hypertension in Patients with Ovarian and Cervical Cancer Receiving Bevacizumab in the Uk. British Journal of Cancer, 121, 109-116. [Google Scholar] [CrossRef] [PubMed]
|
|
[22]
|
籍灵超, 贾婧杰, 张静, 等. 遗传性出血性毛细血管扩张症诊断和治疗国际指南[J]. 中国医学文摘(耳鼻咽喉科学), 2014, 29(1): 40-55.
|